Policy Watch: 20 Regulatory Updates — June 21, 2026
This Policy Watch covers schedules of controlled substances placement June 2026 updates with 20 key regulatory items. The DEA's recent actions focus on synthetic cannabinoids and other substances. These changes affect clinical relevance and regulatory…
Policy Watch: 20 Regulatory Updates — June 19, 2026
This update covers the DEA Schedule I synthetic cannabinoids control update as of June 19, 2026. It details regulatory actions impacting synthetic cannabinoids and related substances. The report informs clinical practice and legal considerations.
Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
The DEA has enacted synthetic ketamine analog regulation by temporarily placing 2-fluorodeschloroketamine in Schedule I. This action highlights the challenges of controlling emerging designer drugs. Clinicians should monitor these regulatory changes…
Schedules of Controlled Substances: Placement of Clonazolam, Diclazepam, Etizolam, Flualprazolam, and Flubromazolam in Schedule I
The DEA scheduling benzodiazepine analogs in Schedule I addresses the abuse potential of synthetic benzodiazepines. These substances pose significant clinical risks and regulatory challenges. Clinicians should be vigilant for exposure to these…
Temporary Scheduling of Bromazolam and Novel Benzodiazepines
The temporary scheduling of novel benzodiazepines such as bromazolam reflects regulatory efforts to address emerging abuse risks. This update highlights clinical toxicology concerns and enforcement under the Controlled Substances Act. Clinicians should…
Virginia Lawmakers Push Back on Governor’s Cannabis Amendments (Newsletter: April 15, 2026)
Virginia cannabis regulation updates are creating uncertainty for patient access to medical cannabis. Lawmakers are pushing back on gubernatorial amendments, impacting clinical practice. These regulation updates highlight the need for clinicians to…
Tennessee Republicans Halt Medical Marijuana Path After Federal Shift
Tennessee Republicans medical marijuana policy has paused progress on legislation following federal cannabis scheduling changes. This shift affects patient access to legal medical cannabis in Tennessee. Patients and clinicians should prepare for…
Idaho Lawmakers Approve Resolution Asking Voters To Reject Medical Cannabis Ballot Measure
Idaho medical cannabis opposition is growing as lawmakers approve a resolution urging voters to reject the medical cannabis ballot measure. This legislative stance limits patient access to cannabis-based therapies. Clinicians must understand the impact…
Massachusetts Cannabis Reform Bill Expected to Pass Legislature
Massachusetts cannabis reform legislation 2026 is expected to pass both the House and Senate, reshaping the state's cannabis regulatory landscape. This legislation will influence clinical practice by clarifying prescribing pathways and product safety…
Schedule I Drug Classification: 3 Times Science Was Ignored
This meme isn’t exaggeration—it’s history repeating itself in policy. The Schedule I drug classification was meant to indicate substances with a high potential for abuse and no accepted medical use. But as science has evolved, that definition…